Sign up for the QMED & MD+DI Daily newsletter.
Drop the 'Remote', It's Just Patient Monitoring
Dr. Jim Mault, BioIntelliSense CEO, breaks down the rise of remote patient monitoring and explains why it’s time to drop the term for this episode of Let's Talk Medtech.
October 6, 2022
1 Min Read
Image Courtesy of BioIntellisense
Remote patient monitoring has been around for some years now, but the pandemic helped catapult the sector to the forefront.
The forecast for the remote patient monitoring market shows that it’s expected to reach $175 billion by 2027 from $53.6 billion in 2022 during the forecast period, according to a report from Markets and Markets.
It’s a market that BioIntelliSense is making an impact in. The firm has developed the BioButton, multi-parameter wearable device and advanced data services for continuous vital sign monitoring.
Jim Mault, MD, BioIntelliSense CEO and founder spoke about the rise of the market and why remote patient monitoring is a misnomer in this all-new episode of Let’s Talk Medtech.
About the Author(s)
You May Also Like
Pedersen's POV graphic featuring the headshot of MD+DI Senior Editor Amanda Pedersen and a pull quote from the latest edition of her opinion column.
BioSig's Ridiculously Sparse Layoff Announcement Reeks of CallousnessFeb 26, 2024|3 Min Read
Sourcing Electrical Components: Are We Back to Normal?Feb 26, 2024|6 Min Read
Your Smartwatch Can’t Measure Blood Glucose Levels… YetFeb 26, 2024|3 Min Read
Medtech in a Minute: Medtronic Pulls the Plug on Ventilators and MoreFeb 26, 2024|1 Min Read